Skip to content

Study on the correlation between gene polymorphism in patients with psoriasis and methotrexate efficacy and adverse reactions

Study on the correlation between gene polymorphism in patients with psoriasis and methotrexate efficacy and adverse reactions

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034863
Enrollment
Unknown
Registered
2020-07-22
Start date
2020-08-01
Completion date
Unknown
Last updated
2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

Psoriasis group:Methotrexate
healthy control group:Nil

Sponsors

Dermatological Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with moderate to severe psoriasis vulgaris; 2. Can receive long-term low-dose MTX treatment.

Exclusion criteria

Exclusion criteria: 1. Younger than 16 years of age; 2. Women who are pregnant or breastfeeding; 3. Those who have a birth control plan within the past 3 months; 4. Alcoholism; 5. People who have mental illness or are unable to cooperate with treatment; 6. Infectious diseases such as tuberculosis, etc. that are active at the same time; 7. Those with immunodeficiency; 8. Serious systemic diseases such as abnormal liver and kidney function, viral hepatitis or cirrhosis, liver transaminase, blood creatinine and urea nitrogen Those who exceed 1.5 times the upper limit of normal, blood system diseases (white blood cell count < 4 * 10^9/L, hemoglobin <80g/L, platelets < 100 * 10^9/L); 9. Hepatotoxicity in the past 3 months Drug users.

Design outcomes

Primary

MeasureTime frame
PASI score;

Countries

China

Contacts

Public ContactHua Weiwei

Dermatological Hospital, Chinese Academy of Medical Sciences

huaweiwei1993@163.com+86 18761873104

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026